Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 29, 2007. The report details a specific corporate action regarding share repurchases authorized by shareholders at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to a share buyback.
- Shares Purchased: 1,400,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,388.3476 pence per share.
- Treasury Shares Held: 279,982,678 shares following the transaction.
- Shares in Issue: 5,730,403,296 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding shares through the acquisition of 1,400,000 shares for Treasury. The filing does not provide comparative financial data against prior periods to assess broader material changes in operations or financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance notification confirming the execution of a share repurchase in conformity with the Transparency Directive's transitional provision 6.
Investor Verification Checklist
- Verify the total number of Treasury shares held (279,982,678) against subsequent filings.
- Confirm the total shares in issue (5,730,403,296) for calculating voting rights and ownership thresholds under FSA Disclosure and Transparency Rules.
- Note that this announcement does not constitute an offer to purchase or subscribe for securities.